ADvantage Therapeutics

Website
Current Valuation
$81.0M
As of July 28, 2025
Total Funding Raised
$18.7M
Last Round
Seed Round

$13.7M

Last Funding
Jul 2025

Funding date

Capital Efficiency
4.32x

Valuation / Funding

Funding History & Valuation Timeline
Complete history of all funding rounds and valuation milestones

No funding history available

Funding data has not been imported for this company yet

Valuation Analysis

Current Valuation Metrics

ADvantage Therapeutics is currently valued at $81.0M as of July 28, 2025. The company has raised a total of $18.7M in funding.

Capital Efficiency

With a capital efficiency ratio of 4.32x, ADvantage Therapeutics has achieved a valuation that is 4.32 times the total capital raised.

Track ADvantage Therapeutics Valuation Updates

Get notified when ADvantage Therapeutics raises new funding or valuation changes

Explore More Data
Detailed analysis for ADvantage Therapeutics

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

See full funding history

Sign up to view ADvantage Therapeutics's complete funding timeline, round details, and valuation progression.

Trade ADvantage Therapeutics shares on the secondary market

Premier Alternatives facilitates secondary transactions for accredited investors.

What is ADvantage Therapeutics Worth in 2026?

ADvantage Therapeutics is a leading private company in the technology sector. Track ADvantage Therapeutics's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How ADvantage Therapeutics Valuation is Determined

Private company valuations like ADvantage Therapeutics's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.